In osteoporosis patients, daily treatment with teriparatide and PTH1–84 elicits greater increases in bone formation markers (≥80 % for serum bone-specific alkaline phosphatase concentration relative to the pre-treatment levels) than in bone resorption markers (≥100 % for urinary type I collagen N-telopeptide (NTX/creatinine) relative to the pre-treatment level), thereby accelerating bone turnover, and promoting an increase in bone mineral density (BMD) [3, 6]. This evidence concerns the gene PTH and osteoporosis.